DK1604674T3 - Anvendelse af myoblaster til fremstilling af et medikament til behandling af stressinkontinens - Google Patents

Anvendelse af myoblaster til fremstilling af et medikament til behandling af stressinkontinens

Info

Publication number
DK1604674T3
DK1604674T3 DK05000057T DK05000057T DK1604674T3 DK 1604674 T3 DK1604674 T3 DK 1604674T3 DK 05000057 T DK05000057 T DK 05000057T DK 05000057 T DK05000057 T DK 05000057T DK 1604674 T3 DK1604674 T3 DK 1604674T3
Authority
DK
Denmark
Prior art keywords
manufacture
myoblasts
drug
treatment
stress incontinence
Prior art date
Application number
DK05000057T
Other languages
English (en)
Inventor
Michael B Chancellor
Johnny Huard
Original Assignee
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22181500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1604674(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Pittsburgh filed Critical Univ Pittsburgh
Application granted granted Critical
Publication of DK1604674T3 publication Critical patent/DK1604674T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C12N5/0659—Satellite cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK05000057T 1998-05-01 1999-04-30 Anvendelse af myoblaster til fremstilling af et medikament til behandling af stressinkontinens DK1604674T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8391798P 1998-05-01 1998-05-01
PCT/US1999/009451 WO1999056785A2 (en) 1998-05-01 1999-04-30 Cell mediated gene delivery using muscle derived cells for treating muscle-and bone-related injury or dysfunction

Publications (1)

Publication Number Publication Date
DK1604674T3 true DK1604674T3 (da) 2009-03-23

Family

ID=22181500

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05000057T DK1604674T3 (da) 1998-05-01 1999-04-30 Anvendelse af myoblaster til fremstilling af et medikament til behandling af stressinkontinens
DK08169379.8T DK2075002T3 (da) 1998-05-01 1999-04-30 Myoblaster til reparation af urinvejslukkemuskel

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK08169379.8T DK2075002T3 (da) 1998-05-01 1999-04-30 Myoblaster til reparation af urinvejslukkemuskel

Country Status (8)

Country Link
EP (3) EP2075002B1 (da)
AT (2) ATE414524T1 (da)
AU (1) AU3775799A (da)
CA (1) CA2330660C (da)
DE (2) DE69939956D1 (da)
DK (2) DK1604674T3 (da)
ES (2) ES2419029T3 (da)
WO (1) WO1999056785A2 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6866842B1 (en) 1998-05-01 2005-03-15 University Of Pittsburgh Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction
US7115417B1 (en) 1998-05-01 2006-10-03 Chancellor Michael B Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof
US8211423B2 (en) 2006-11-28 2012-07-03 University Of Pittsburgh Muscle derived cells for the treatment of cardiac pathologies and methods of making and using the same
US6706682B2 (en) 1999-01-21 2004-03-16 The Trustees Of Columbia University In The City Of New York Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
AU778047B2 (en) * 1999-05-03 2004-11-11 Kolon Tissuegene, Inc. Gene therapy using TGF-beta
US6315992B1 (en) 1999-06-30 2001-11-13 Tissuegene Co. Generating cartilage in a mammal using fibroblasts transfected with a vector encoding TGF-β-1
US7338655B1 (en) 1999-06-30 2008-03-04 Tissuegene, Inc. Gene therapy using TGF-β
US20020193301A1 (en) 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
AU6920800A (en) * 1999-08-19 2001-03-13 Stem Cell Pharmaceuticals, Inc. Tgf-alpha polypeptides, functional fragments and methods of use therefor
PT1272204E (pt) * 2000-04-14 2007-10-02 Univ Pittsburgh Aumento e enchimento de tecidos moles e osso utilizando células progenitoras derivadas de músculo, suas composições e tratamentos
FR2810045B1 (fr) * 2000-06-07 2004-09-03 Assist Publ Hopitaux De Paris Procede d'obtention de population cellulaires caracterisees d'origine musculaire et utilisations
WO2002067867A2 (en) * 2001-02-23 2002-09-06 The University Of Pittsburgh Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair
CN1812800B (zh) 2003-04-25 2013-01-16 匹兹堡大学 用于促进和增强神经修复和再生的肌肉来源的细胞(mdc)
JP5570814B2 (ja) 2006-12-18 2014-08-13 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 胃食道病理学を処置するための筋由来細胞ならびにその作成法および使用法
US20100158875A1 (en) 2006-12-18 2010-06-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Muscle derived cells for the treatment of gastro-esophageal pathologies and methods of making and using the same
EP2118271B1 (en) 2007-01-11 2018-04-18 University of Pittsburgh - Of the Commonwealth System of Higher Education Muscle derived cells for the treatment of urinary tract pathologies and methods of making and using the same
JP2010529888A (ja) * 2007-06-15 2010-09-02 エシコン・インコーポレイテッド 失禁治療のための組織断片組成物
AU2009282619B2 (en) * 2008-08-18 2015-08-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof
WO2014040030A1 (en) * 2012-09-10 2014-03-13 Wake Forest University Health Sciences Urine stem cells for skeletal muscle generation and uses thereof
EP3511412A1 (en) 2018-01-12 2019-07-17 Genethon Genetically engineered hematopoietic stem cell as a platform for systemic protein expression
US10610280B1 (en) 2019-02-02 2020-04-07 Ayad K. M. Agha Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat
WO2020238961A1 (en) * 2019-05-29 2020-12-03 Institute Of Zoology, Chinese Academy Of Sciences Compositions and use of engineered myogenic cells
WO2024115761A1 (en) 2022-12-01 2024-06-06 Universität Zürich Method of preparing a mass culture of muscle precursor cells (mpcs) and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130141A (en) 1988-05-24 1992-07-14 Law Peter K Compositions for and methods of treating muscle degeneration and weakness
US5538722A (en) 1989-06-13 1996-07-23 Stanford University Isolation, growth, differentiation and genetic engineering of human muscle cells
US5658565A (en) 1994-06-24 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inducible nitric oxide synthase gene for treatment of disease
CA2150125A1 (en) 1992-11-25 1994-06-09 Timothy R. Billiar Cdna clone for human inducible nitric oxide synthase and process for preparing same
US5594032A (en) * 1994-11-10 1997-01-14 Gonzalez-Cadavid; Nestor F. Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA
SG74036A1 (en) * 1994-12-13 2000-07-18 Peter K Law Instrument for cell culture
US6150338A (en) * 1997-02-13 2000-11-21 Albert Einstein College Of Medicine Of Yeshiva University Gene therapy for alleviating erectile dysfunction

Also Published As

Publication number Publication date
WO1999056785A3 (en) 2001-04-19
EP1604674B1 (en) 2008-11-19
AU3775799A (en) 1999-11-23
CA2330660C (en) 2012-04-10
EP2075002A3 (en) 2009-07-08
CA2330660A1 (en) 1999-11-11
DE69936785D1 (de) 2007-09-20
DE69939956D1 (de) 2009-01-02
ATE414524T1 (de) 2008-12-15
DK2075002T3 (da) 2013-05-21
EP2075002A2 (en) 2009-07-01
EP2075002B1 (en) 2013-02-13
EP1113807A2 (en) 2001-07-11
EP1604674A2 (en) 2005-12-14
EP1604674A3 (en) 2005-12-21
EP1113807B1 (en) 2007-08-08
WO1999056785A2 (en) 1999-11-11
ES2419029T3 (es) 2013-08-19
ES2319660T3 (es) 2009-05-11
ATE369141T1 (de) 2007-08-15

Similar Documents

Publication Publication Date Title
DK1604674T3 (da) Anvendelse af myoblaster til fremstilling af et medikament til behandling af stressinkontinens
DK1459749T3 (da) (S,S)-reboxetin til behandling af inkontinens
TR200302214T4 (tr) Psoriasis tedavisi için kullanilan pteridine bileşkenleri
BR0211281A (pt) Dispositivo para tratamento de aneurisma
DK0453127T3 (da) Behandling af katarakt med 15-keto-prostaglandinforbindelser
DK1047406T3 (da) Autoklaverbar farmaceutisk sammensætning indeholdende en chelatdanner
DK0691130T3 (da) Anvendelse af rapamycin til fremstilling af et lægemiddel til forebyggelse og behandling af hyperproliferative vaskulære sygdomme, eventuelt i kombination med mycophenolsyre
IL213649A0 (en) Prodrugs of gabapentin compounds, compositions and their use in the manufacture of a medicament
CY2005002I1 (el) Χρηση της βενλαφαξινης ή μιας ενωσης αρυλοξυ προπαναμινης για την παρασκευη ενος φαρμακου για την αγωγη της ουρικης ακρατειας
NO20031018D0 (no) Oksymorfonpreparater med kontrollert frigivelse
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
PT1349856E (pt) Compostos de isoindolina-1-ona activadores da glicocinase
DK0979079T3 (da) Anvendelse af tetrahydropyridinderivater til fremstilling af lægemidler til behandling af sygdomme, der medförer en demyelinisering
NO994165D0 (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
DK1007055T3 (da) Anvendelse af amifostin
IT1318514B1 (it) Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
IT1318667B1 (it) Medicamento antinfiammatorio.
IS6087A (is) N-(2-fenýl-4-amínó-bútýl)-1-naftamíð sem virka á móti taugakínín-1 viðtaka
BR0115882A (pt) Emprego de compostos de 1-fenil-3-dimetilaminopropano no tratamento da incontinência urinária
DK1434588T3 (da) 2-(amino-3,4-dioxo-1cyclobuten-1-yl)aminoalkylsyrederivater til behandling af smerte
DK0617959T3 (da) Lægemiddel til behandling af hudsygdomme
NO20032411L (no) Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens
BR0208593A (pt) método para o tratamento de um mamìfero, composto, e, composição farmacêutica
DK1390364T3 (da) Aryl-8-azabicyclo[3.2.1]octaner til behandling af depression